Daniel Donner
Research Officer
Experimental Cardiology
Baker Heart and Diabetes Institute
Australia
Biography
Dr Daniel Donner graduated from Griffith University (Queensland) with a Bachelor of Biomedical Science (2008) before completing a Masters of Medical Research (2010). In 2011, he was granted an Australian Postgraduate Award to pursue a PhD in cardiovascular research and received an Australian Government scholarship to commence parallel study within the National Commercialisation Training Scheme. Throughout his doctoral studies, his research concentrated on the development of novel models of disease for the evaluation of selective androgen receptor therapies in the treatment of obesity and diabetes. Before completing his PhD (2015), Dr Donner had also completed a Graduate Certificate in Research Management (2012); and co-authored 9 peer-reviewed publications, a text book chapter, and over 15 abstracts at national and international scientific meetings. Daniel has been interviewed on live national television and radio, and in national/regional newspapers for his expertise in the cardiovascular risks associated with both high and subsequently low testosterone resulting from anabolic steroid abuse. Dr Donner joined the Baker Heart and Diabetes Institute in 2017 as a member of the Institute’s microsurgery and imagery platform, bringing with him extensive experience in the development and characterisation of novel cardiovascular disease models.
Research Interest
Experimental Cardiology
Publications
-
Daniel Donner,Impact of diet-induced obesity and testosterone deficiency on the cardiovascular system: a novel rodent model representative of males with testosterone-deficient metabolic syndrome (TDMetS) PLoS One 2015 10(9): e0138109.
-
Daniel Donner,The effects of visceral obesity and androgens on bone: trenbolone protects against loss of femoral bone mineral density and structural strength in viscerally obese and testosterone-deficient male rats Osteoporosis International 2015 27(3): 1073–82.
-
Daniel Donner,Trenbolone improves cardiometabolic risk factors and myocardial tolerance to ischemia-reperfusion in male rats with testosterone-deficient metabolic syndrome Endocrinology 2016 157(1): 368–81.
